Glucagon-like insulinotropic peptides, compositions and methods

Details Glucagon-like insulinotropic peptides, compositions and methods Glucagon-like insulinotropic peptides, compositions and methods

1997-09-10

1999-11-02

Richter, Johann

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514866, 530308, 530324, A61K 3800

Patent

active

059770716

ABSTRACT:
The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.

REFERENCES:
patent: 4347374 (1982-08-01), Kollonitsch et al.
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5705483 (1998-01-01), Galloway et al.
Komatsu, R., et al., Diabetes, 38:902-905 (1989).
Orskov, C., et al., J. Biol. Chem., 264(22) :12826-12829.
Mojsov, S., Int. J. Peptide Protein Res., 40:33-343 (1989).
Holz, G.G., et al., Nature, 361:362-365 (1993).
Orskov, C., Diabetologia, 35:701-711 (1992).
Mentlein, R., et al., Eur. J. Biochem., 214:829-835 (1993).
Handbook of Experimental Pharmacology, Springer-Verlag, Hasselblatt, et al., (Eds.), 32(2):729-777 (1975).
Nauk, M.A., et al., J. Clin. Invest., 91:301-307 (1993).
Nauk, M.A., et al., Diabetologia, 36:741-744 (1993).
Gutniak, M., et al., N. E. J. Med., 326(20):1316-1322, (1992).
Thorens, B., et al., Diabetes, 42:1219-1225 (1993).
Levine-Pinto, H. et al., Biochem. Biophys. Res. Commun., 103(4):1121-1130 (1981).
Owa, T., et al., Chem. Letters: 873-874 (1988).
Altman, J., et al., Synthetic Commun., 19(11 & 12):2069-2076 (1989).
O'Donnell, J.J., et al., Synthetic Commun., 19(7 & 8): 1157-1165 (1989).
Galloway, J.A., Diabeties Care, 13:1209-1239, (1990).
Galloway, J.A., et al., Clin. Therap., 12:460-472, (1990).
Suzuki, S., et al., Endocrinology, 125, 3109-3114, (1990).
Ananthanancayanan, V.V., et al., Mol. Biol. Cell (Supp) 3, 250A (1992).
Epand, R.M., Mol. Pharmacol., 22:105-108 (1982).
Pridal, L., et al., "Absorption of Glucagon-Like Peptide-1 Can Be Protracted by Zinc or Protamine", International Journal of Pharmaceuticals, 136 (1996) 53-59.
AN 1995:257836, EP 619322 A2, abstract, Oct. 12, 1994.

Affiliated with

Also associated with

Rating

Glucagon-like insulinotropic peptides, compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Glucagon-like insulinotropic peptides, compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucagon-like insulinotropic peptides, compositions and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2135528